Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

Go back to Celcuity (CELC) Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
CEL Communications, Inc. (NASDAQ: CELC) Delayed: 25.92 +0.75 (2.98%)
Previous Close $25.17    52 Week High $0.00 
Open $23.68    52 Week Low $0.00 
Day High $26.25    P/E N/A 
Day Low $23.60    EPS $0.00 
Volume 58,561